Compare Dyne Therapeutics Inc. Common Stock (DYN) vs Intuitive Surgical, Inc. (ISRG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs Intuitive Surgical, Inc. — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.06 (market cap $2.86B), while Intuitive Surgical, Inc. trades at $424 (market cap $149.10B). The key difference: Intuitive Surgical, Inc. is far larger — about 52.1× Dyne Therapeutics Inc. Common Stock's market cap, and Intuitive Surgical, Inc. is trading nearer its 52-week high, Dyne Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and Intuitive Surgical, Inc. for 84 Days on average.
| DYN | ISRG | |
|---|---|---|
Market Cap | $2.86B | $149.10B |
Volume | 3,341,579 | 1,732,647 |
Sector | Health | Health |
52-Week High | $26.78 | $592.85 |
52-Week Low | $14.60 | $332.02 |
Typical Hold Time | 0 Days | 84 Days |
Enterprise Value | $2.18B | $143.89B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
Intuitive Surgical (ISRG) trades at $420.24, down 1.73% on the day, but maintains strong fundamentals with consistent earnings beats and robust revenue growth. The company reported $10.06B in 2025 revenue with 28.45% net margins, while technical indicators show a bullish trend with support at $414. Recent news highlights international expansion in India and Japan to offset China weakness.
ISRG presents a compelling investment case with 70% analyst buy ratings and a $480.78 price target offering 14% upside. Key risks include competitive pressures in robotic surgery and procedure growth concerns, but the company's market leadership and recurring revenue model support long-term growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About Intuitive Surgical, Inc.
Intuitive Surgical develops, produces, and markets a robotic system for assisting minimally invasive surgery. It also provides the instrumentation, disposable accessories, and warranty services for the system. The company has placed nearly 7,000 da Vinci systems in hospitals worldwide, with more than 4,000 installations in the United States and a growing number in emerging markets.
Read more on ISRG →
